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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
A nonsense polymorphism in the protein Z–dependent protease inhibitor increases
the risk for venous thrombosis
Javier Corral, Rocio Gonza´lez-Conejero, Jose Manuel Soria, Jose Ramo´n Gonza´lez-Porras, Elena Pe´rez-Ceballos, Ramo´n Lecumberri,
Vanessa Rolda´n, Juan Carlos Souto, Antonia Min˜ano, David Herna´ndez-Espinosa, Ignacio Alberca, Jordi Fontcuberta, and Vicente Vicente
The protein Z–dependent protease inhibitor
(ZPI) is a hemostatic serpin with anticoagu-
lant activity. As for antithrombin, deficiency
of ZPI could have relevant thrombotic conse-
quences. We have studied 6 genetic modifi-
cations affecting the ZPI gene, identifying 5
haplotypes. Haplotype H5 is featured by a
stop codon at position 67. The relevance of
these genetic modifications and haplotypes
in venous thrombosis was evaluated in a
case-control study including 1018 patients
and 1018 age- and sex-matched controls.
Surprisingly, the H5 haplotype was found in
0.9% of controls, supporting that the
Arg67Stop change is a low frequency non-
sense polymorphism. The prevalence of this
haplotype increased significantly in pa-
tients (3.0%), one of whom was in a homozy-
gous state. Multivariate analysis confirms
that carriers have a 3.3-fold risk of develop-
ing venous thrombosis (P .002; 95% CI:
1.5-7.1). Moreover, we observed a signifi-
cant association of this polymorphism with
familial history of thrombosis (P< .001). Our
study supports that the ZPI Arg67Stop non-
sense polymorphism might be an indepen-
dent genetic risk factor for venous thrombo-
sis. This polymorphism has slightly lower
prevalence but similar thrombotic risk than
the FV Leiden or prothrombin 20210A. Al-
though further studies are required, all avail-
able data support that the ZPI is a candidate
to play a significant role in thrombosis and
should be evaluated in thrombophilic stud-
ies. (Blood. 2006;108:177-183)
© 2006 by The American Society of Hematology
Introduction
Initially, venous thrombosis was considered a monogenic disease,
as rare mutations affecting some anticoagulant proteins (antithrom-
bin, protein C, and protein S) identified in thrombophilic families
significantly increased (more than 8-fold) the risk for venous
thrombosis.1 However, the consensus about the relevance in venous
thrombosis of 2 polymorphisms (factor V Leiden and prothrombin
20210) supported that venous thrombosis is a multigenic disease.2
Accordingly, common genetic variations with mild associated risk
could play a role in this disorder.2 Unfortunately, despite a
considerable effort during 2 decades evaluating hundreds of
polymorphisms affecting hemostatic proteins, no further genetic
risk factors for venous thrombosis have been clearly identified.3
One possible explanation of these frustrating results is that the
screening of candidate polymorphisms has been exclusively fo-
cused on classic hemostatic proteins. It would be interesting to
evaluate further candidates that might play a role in hemostasis.
The precise role of the protein Z–dependent protease inhibitor
(ZPI) is uncertain, but in vitro studies suggest that it might be a
potent anticoagulant. Its name derives from the role that protein Z
(PZ) plays in enhancing its function. ZPI is a 72-kDa member of
the serpin superfamily of serin protease inhibitors (SERPINA10)
with tyrosine-serine as the P1-P1 residues.4 Nevertheless, ZPI
efficiently inhibits both factor Xa and factor XIa by 2 different
mechanisms.5 In plasma, PZ completely complexes all ZPI. In
the presence of procoagulant phospholipids and calcium, the
PZ-ZPI complex produces rapid inhibition of factor Xa (t1/2  10
seconds, at a rate 1000-fold faster than ZPI alone).5 Factor XIa
inhibition by ZPI is not dependent on PZ, phospholipids, or
calcium, but is enhanced by heparin.5 In contrast to other
anticoagulant serpins, the inhibitory complex FXa-ZPI seems to
be quite unstable, and the inactivation of FXIa also produced
cleaved ZPI. Accordingly, the ZPI activity is consumed during
the in vitro coagulation of plasma.5 A recent paper supports that
the ZPI may be an unusual physiologic regulator of both the
intrinsic FXase and the prothrombinase complexes.6 The pos-
sible relevance of this system in regulating the coagulation
response and in thrombosis arises from the PZ knock-out mice,
which indicated that PZ appears to dampen the prothrombotic
response. Moreover, the PZ-deficient mice exhibited prothrom-
botic tendency in combination with factor V Leiden.7 Recently,
one nonsense mutation within the ZPI gene (Trp303Stop) was
identified in 3.8% of patients with venous thrombosis but not in
controls.8 All of these data support a relevant role of this
molecule in venous thrombosis. Therefore, this gene is a
candidate to exhibit other genetic changes that might influence
the risk of venous thrombosis.
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Patients, materials, and methods
Patients and controls
Our study included 1018 consecutive and unrelated white patients with a
first, objectively confirmed episode of venous thromboembolism before the
age of 75 years. These patients were enrolled from the files of the
anticoagulation clinics in 4 hospitals in Spain: Hospital General Universita-
rio (Murcia), Hospital de la Santa Creu i Sant Pau (Barcelona), Hospital
Clı´nico Universitario (Salamanca), and Clı´nica Universitaria de Navarra
(Pamplona). All cases were diagnosed appropriately by clinical probability,
D-dimer levels, compression ultrasonography, ventilation perfusion lung
scan, and, when necessary, phlebography or pulmonary angiography.
Patients with known malignant disorders were excluded. The control group
of our study included 1018 unrelated people without a history of vascular or
thromboembolic disease. These controls were randomly selected among 2
sources: blood donors and traumatology and ophthalmology patients
matched by age, sex, race, and geographic distribution with 1018 cases.
All included subjects gave their informed consent to enter the study,
which was performed in accordance with the Declaration of Helsinki as
amended in Edinburgh in 2000. Approval for this study was obtained from
the institutional review boards of Hospital General Universitario (Murcia,
Spain), the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain),
Hospital Clı´nico Universitario (Salamanca, Spain) and Clı´nica Universita-
ria de Navarra (Pamplona, Spain).
Demographic parameters (age and sex) were recorded in all subjects.
Moreover, a list of other clinical data (familial history of venous thrombo-
sis, recurrence, type of thrombotic event, location of the thrombosis, and
other thrombotic risk factors such as use of oral contraceptives, hormone
replacement therapy, phospholipid antibodies, and protein C, protein S, or
antithrombin deficiency) were recorded.
Genetic analysis
Blood was collected from the antecubital vein into citrate tubes (0.1 volume
0.106 M trisodium citrate), and genomic DNA was purified. Amplification
of the 4 coding exons of the ZPI gene (exons 2-5) was performed by
polymerase chain reaction (PCR) using the primers described by Van de
Water et al,8 with minor modifications. The 1277GA (Gly250Ser)
polymorphism was genotyped by single-strand conformation polymor-
phism (SSCP). The 1276CT (Tyr249) polymorphism was determined by
SSCP and confirmed by PCR-ASRA using the RsaI enzyme. The 1438GA
(Trp303Stop) mutation was evaluated by SSCP and PCR–allelic specific
restriction assay (ASRA) with HinfI. The 603AG (Lys25Arg), 647AG
(Ser40Gly), and 728CT (Arg67Stop) polymorphisms were evaluated by
SSCP and PCR-ASRA with Eco130I, MspI, and SatI, respectively. Confir-
mation of the identified genotypes for all polymorphisms was performed by
sequence analysis.
Moreover, the factor V (FV) Leiden and prothrombin (PT) 20210GA
polymorphisms were determined in all patients and controls as described.9
Statistical analysis
Results are expressed as median value and interquartile ranges for
continuous variables and as percentages for categoric variables. Univariate
statistical analysis was performed by the chi-square test. The strength of the
association of major risk factors and the polymorphism with the occurrence
of disease was estimated by calculation of the odds ratio (OR) with EpiInfo
software (Centers for Disease Control and Prevention, Atlanta, GA) and the
Cornfield method for the calculation of 95% confidence intervals (CIs).10
Multivariate analysis was performed using logistic regression enter method,
with the SPSS statistical package for Windows 8.0 software (Chicago, IL).
Differences with a 2-tailed P value less than .05 were considered
statistically significant.
We tested the null hypothesis that Hardy-Weinberg equilibrium holds
using the chi-square method. We calculated the P value by simulation with
100 000 replicates.
Linkage disequilibrium (LD) between each pair of SNPs was estimated by
the pairwise correlation (r) among genotypes. Working with SNPs, this measure
is equivalent to the correlation of Weir11 (Appendix A in Meng et al12).
Haplotype analysis with unrelated individuals has to face up to the
problem of ambiguity of haplotypes; that is, many individuals are consistent
with different haplotype configurations. We used the likelihood approach
described previously to estimate the haplotypes.13 This method, in addition
to estimating haplotype frequencies, computes the posterior probabilities of
the pairs of haplotypes that are consistent with the observed markers for
each subject. Then, to evaluate the association of the affection status with
haplotypes, we applied the score method that uses those posterior probabili-
ties to account for haplotype ambiguities.14 Based on generalized linear
models, this approach can be applied to binary, ordinal, and quantitative
traits and, at the same time, allow adjustment for nongenetic covariates,
which may be critical when analyzing genetic complex traits. In our case,
we used FV Leiden and PT as covariates.
All genetic calculations were done with the statistical environment R
(The R Project for Statistical Computing, http://www.r-project.org).
Results
Identification of genetic variations in the ZPI gene
In a previous study of our group, we evaluated the ZPI Trp303Stop
mutation in 218 Spanish patients with venous thrombosis by
PCR-ASRA and SSCP. No patient carried the Trp303Stop non-
sense mutation.15 However, the SSCP analysis and ulterior se-
quence revealed 2 variations in the published sequence of ZPI exon
3: 1276CT silent mutation (Tyr249) and 1277GA point muta-
tion, responsible for the Gly250Ser missense change (nucleotide
and amino acid numbering as per mRNA GenBank entry AF181467)
(Figure 1A). Of interest, these mutations are consecutive. The first
modification, also identified by Van de Water et al,8 was recognized
as a possible SNP in the NCBI SNPs database (ID: rs2232707).16
The second change was also identified in the New Zealand cohort,8
and it was present in 8 patients with venous thrombosis from our
preliminary study. This change was also present in the NCBI SNPs
database (ID: rs2232708).16
Additionally, we sequenced all coding exons of the ZPI gene (exons
2-5) of 5 carriers of the ZPI Gly250Ser polymorphism using primers and
conditions previously reported.8 No subject had further genetic modifi-
cations on exons 3, 4, and 5. However, we identified 3 genetic changes
in the 5-end of exon 2 (Figure 1B), a region homologous to that of
another hemostatic serpin: heparin cofactor II,17 which encodes the
acidic tail of the N-terminus of the ZPI molecule.All Gly250Ser carriers
simultaneously had a 603AG transition (responsible for the Lys25Arg
missense modification). Of interest, 4 subjects also had a 728CT point
mutation, which causes a nonsense change (Arg67Stop) in heterozygous
state. Finally, only one patient also had the 647AG (Ser40Gly)
variation (Figure 1B). All of these modifications were also identified by
Van de Water et al8 and are present in the NCBI SNPs database ID:
Lys25Arg, rs941590; Arg67Stop, rs2232698; Ser40Gly, rs941591.16
Unfortunately, the frequency and the role in venous thrombosis
of these genetic modifications were not clearly defined. Accord-
ingly, we extensively evaluated these 5 SNPs and the Trp303Stop
mutation of the ZPI gene on a large cohort of patients with venous
thrombosis and controls.
Case-control study
Demographic, clinical, and genetic data of cases and controls are
presented in Table 1. These features did not significantly differ in
the samples from the 4 hospitals (data not shown).
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The median age of patients at the time of the first thrombotic
event was 45 years (interquartile ranges, 33-58), and the ratio of
males to females was 1:1. Approximately two thirds of the patients
suffered a single thrombotic episode (280 of 1018 had recurrent
episodes of venous thrombosis). Moreover, 218 patients reported
risk factors such as use of oral contraceptives, antiphospholipid
antibodies, or hormone replacement therapy, and deficiency of
antithrombin, protein C, or protein S. Finally, 177 patients (17.4%)
reported familial history of thrombosis.
The prevalence of the classic prothrombotic polymorphisms
was similar to that described in other series. Thus, the FV Leiden
was present in 145 patients (3 in homozygous state; 14.2%), and
Figure 1. Identification of genetic variations in the ZPI encoding gene. (A) Variations in exon 3. (B) Variations in 5-end of exon 2. MW indicates molecular weight marker
(X174 DNA/HinfI Marker; Promega, Madison, WI).
Table 1. Characteristics of patients with venous thrombosis and control subjects
Patients Control subjects P*; OR (95% CI)
N 1018 1018
Age, y (range) 49 (36–62) 47 (35–63) .618
Male sex, no 509 509 .999
FV Leiden, no.  .001; 5.29 (3.5–8.0)
/ 873 987
/ &/ 142 & 3 31 & 0
PT 20210, no.  .001; 4.20 (2.7–6.7)
G/G 917 992
G/A & A/A 94 & 7 26 & 0
ZPI 603 (Lys25Arg), no. .113
A/A 295 328
A/G & G/G 522 & 201 525 & 165
ZPI 647 (Ser40Gly), no. .959
A/A 759 758
A/G & G/G 246 & 13 249 & 11
ZPI 728 (Arg67Stop), no.  .001; 3.40 (1.5–7.8)
C/C 988 1009
C/T & T/T 29 & 1 9 & 0
ZPI 1277 (Gly250Ser), no.  .001; 3.01 (1.6–5.8)
G/G 977 1004
G/A & A/A 40 & 1 14 & 0
*Crude analysis; OR is given when P .05.
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the PT 20210A allele was identified in 101 patients (7 in
homozygous state; 9.9%) (Table 1). Controls had a significantly
lower prevalence of these prothrombotic polymorphisms: 31
(3.0%) were heterozygous for the FV Leiden and 26 (2.6%), for the
PT 20210A allele (Table 1). Accordingly, these polymorphisms
increased 5.3-fold (FV Leiden) and 4.2-fold (PT 20210A) the risk
of venous thrombosis (P  .001; 95% CI: 3.5-8.0 and P  .001;
95% CI: 2.7-6.7, respectively). The age of the first episode of
venous thrombosis, the percentage of recurrence, the incidence
of additional risk factors, and the history of familial thrombosis
associated with these polymorphisms are shown in Table 2.
In our study, no patient or control carried the ZPI Trp303S-
top mutation.
The ZPI 1276CT silent mutation (Tyr249) was identified in
only one patient with venous thrombosis. This patient suffered
from an idiopathic deep venous thrombosis at the age of 58 years
and reported no familial history of thrombosis. This mutation was
not identified in controls.
The prevalence of other ZPI polymorphisms (1277G  A
[Gly250Ser]; 603AG [Lys25Arg]; 647AG [Ser40Gly]) in
patients and controls is reported in Table 1.
Finally, the ZPI 728CT transition, responsible for a nonsense
change (Arg67Stop), has to be considered as a low prevalence
polymorphism as it was identified in heterozygous state in 9
controls (0.9%). Of interest, this nonsense polymorphism was more
frequent among patients with venous thrombosis (3.0%, Table 1).
Remarkably, one patient was homozygous for this nonsense
variation (Figure 1B). This patient suffered the first episode of
deep venous thrombosis at the age of 62 years when she was
under hormone replacement therapy, and reported familial
history of thrombosis. According to our results, this polymor-
phism increased 3.4-fold the risk of venous thrombosis (P  .001;
95% CI: 1.5-7.8) (Table 1).
The clinical features of carriers and noncarriers of these
polymorphisms are shown in Table 2. No significant differences
were observed when attending to the age of the first episode,
recurrence, presence of additional risk factors, or familial history of
venous thrombosis for all tested polymorphisms except an in-
creased familial history of venous thrombosis among carriers of the
ZPI Lys25Arg, Arg67Stop, and Gly250Ser variants (Table 2).
The allele and genotype frequencies for the present study are
consistent with that predicted by Hardy-Weinberg equilibrium
(data not shown).
ZPI haplotypes
Our results supported strong linkage disequilibrium between 4
polymorphisms of the ZPI gene (603AG, 647AG, 728CT,
and 1277GA) (Table 3) that defined 5 different haplotypes
(Figure 2). The most common haplotype, with an overall frequency
of 0.58 in controls, was wild type at all 4 loci (H1: 603A, 647A,
728C, and 1277G) (Figure 2). All other haplotypes shared the 603G
variant. Of interest, haplotype H5 had the 728T and 1277A
variations. One patient had an H5-variant haplotype (H5v), prob-
ably caused by recombination. Figure 2 also suggests a model that
might explain the origin of these haplotypes.
The distribution of haplotypes in patients and controls is
reported in Table 4. The estimated haplotype frequencies are also
shown in Table 4. We point out that the haplotype H5 was the only
one showing a prevalence statistically higher in patients than in
controls (Table 4).
Table 2. Clinical features of patients according to the ZPI, FV Leiden and prothrombin polymorphisms
No. (%)
Age at first
episode, y (range)
Recurrence,
no. (%)
Other risk
factors, no. (%)
Familial
history, no. (%)
ZPI Lys25Arg
Carrier 723 (71.0) 45 (33-58) 203 (68.8) 164 (22.7) 138 (19.1)
Noncarrier 295 (29.0) 47 (33-60) 77 (26.1) 54 (18.3) 39 (13.2)*
ZPI Ser40Gly
Carrier 259 (25.4) 45 (33-56) 70 (27.0) 58 (22.4) 38 (14.7)
Noncarrier 759 (74.6) 45 (33-59) 210 (27.7) 160 (21.0) 139 (18.3)
ZPI Arg67Stop
Carrier 30 (2.9) 49 (37-63) 11 (36.7) 9 (33.3) 11 (40.0)
Noncarrier 988 (97.1) 45 (33-58) 269 (27.2) 209 (21.2) 166 (16.8)†
ZPI Gly250Ser
Carrier 41 (4.0) 49 (33-63) 11 (29.3) 10 (26.8) 14 (36.6)
Noncarrier 977 (96.0) 45 (33-58) 269 (27.5) 208 (21.3) 163 (16.7)†
FV Leiden
Carrier 145 (14.2) 44 (30-56) 42 (29.0) 31 (21.4) 30 (20.7)
Noncarrier 873 (85.8) 45 (33-59) 238 (27.3) 187 (21.4) 147 (16.8)
PT 20210A
Carrier 101 (9.9) 45 (32-56) 22 (21.8) 21 (20.8) 16 (15.8)
Noncarrier 917 (90.1) 45 (33-59) 258 (28.1) 197 (21.5) 161 (17.6)
*P  .05.
†P  .005.
Table 3. Linkage disequilibrium between each pair of ZPI SNPs
in cases and controls
FV Leiden ZPI 603 ZPI 647 ZPI 728 ZPI 1277
Patients
PT 0.01 0.00 0.01 0.01 0.01
FV Leiden NA 0.03 0.00 0.01 0.04
ZPI 603 NA NA 0.40 0.13 0.18
ZPI 647 NA NA NA 0.06 0.05
ZPI 728 NA NA NA NA 0.83
Controls
PT 0.03 0.04 0.03 0.02 0.02
FV Leiden NA 0.00 0.00 0.02 0.02
ZPI 603 NA NA 0.41 0.08 0.09
ZPI 647 NA NA NA 0.003 0.05
ZPI 728 NA NA NA NA 0.80
NA indicates not applicable.
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The score test for association of traits with haplotypes allows
the introduction of covariates in the model.14 We use FV Leiden and
PT as covariates. Moreover, the score statistic takes into account
the uncertainty in the imputation of haplotypes to unrelated
individuals. The result of this test suggests a clear association
between the haplotypes and the disease (P  .002).
Multivariate analysis including the 2 classic prothrombotic
polymorphisms (FV Leiden and PT 20210GA) confirmed that the
ZPI H5 haplotype is an independent risk factor for venous
thrombosis (P  .002). The risk of venous thrombosis associated
with the ZPI H5 haplotype (ie, the risk of the nonsense ZPI
Arg67Stop polymorphism) is slightly lower than that of FV Leiden
or prothrombin 20210GA polymorphisms (OR  3.32, 95% CI:
1.5-7.1; OR  5.32, 95% CI: 3.6-7.9; OR  4.24, 95% CI: 2.7-6.6,
respectively).
The clinical features of patients according to their ZPI haplo-
type are shown in Table 5. Statistical comparison with carriers of
the common H1 haplotype in homozygous state (reference group)
found that the H5 and H2 haplotypes were associated with familial
history of thrombosis (P  .001) (Table 5).
Finally, no control simultaneously carried the ZPI H5 haplotype
and FV Leiden or prothrombin polymorphisms, but 9 patients did
(4 patients carried the ZPI Arg67Stop and the prothrombin 20210A
variants [0.4%], and 5 patients presented simultaneously the ZPI
Arg67Stop and the FV Leiden polymorphisms [0.5%]). Similarly,
the simultaneous presence of FV Leiden and prothrombin variants
was identified in 14 patients (1.4%) but not in the controls.
Discussion
The members of the serpin superfamily of serine protease inhibi-
tors share a conserved structure and use a unique suicide substrate-
like inhibitory mechanism. Serpins differ from other protease
inhibitors in that they undergo a profound change in topology in
order to entrap their target protease in an irreversible complex. This
extremely efficient mechanism explains the selection of the serpins
to control the proteolytic cascades of higher organisms. Thus,
serpins have a central role in controlling proteinases in many
biologic pathways such as fibrinolysis, inflammation, complement
activation, apoptosis, angiogenesis, and blood coagulation.18 Unfor-
tunately, the molecular flexibility of serpins also renders these
molecules susceptible to even minor factors (genetic or environmen-
tal) that cause dysfunction, by different mechanisms.19 Thus, the
same serpins that are crucial for a normal physiologic function
could also be involved in diseases. Multiple serpins play a
significant role in the hemostatic system: PAI-1, PAI-2, PCI,
heparin cofactor II, 2-antiplasmin, and antithrombin. Mutations
affecting some of these molecules, especially antithrombin, have
been identified in patients with thrombosis.20 The ZPI could be a
new serpin to be included in the list of key molecules of the
hemostatic system. This molecule plays a significant anticoagulant
role as it potently inhibits FXa and FXIa.5,6 Accordingly, impaired
Figure 2. ZPI haplotypes identified in this study and a suggested
model that explains the origin of these haplotypes.
Table 4. Distribution of ZPI haplotypes among patients with venous
thrombosis and control subjects
Patients, no.
(% or frequency)
Controls, no.
(% or frequency)
H1/H1 (reference group) 297 (29.2) 328 (32.2)
H1/H2 337 (33.1) 334 (32.8)
H1/H3 163 (16.0) 182 (17.9)
H1/H4 3 (0.3) 4 (0.4)
H1/H5 & H1/H5v 17 & 1 (1.8) 5 (0.5)*
H2/H2 90 (8.8) 83 (8.1)
H2/H3 77 (7.6) 66 (6.5)
H2/H4 5 (0.5) 1 (0.1)
H2/H5 9 (0.9) 3 (0.3)
H3/H3 13 (1.3) 11 (1.1)
H3/H4 3 (0.3) 0
H3/H5 2 (0.2) 1 (0.1)
H5/H5 1 (0.1) 0
H1 (reference group) 1115 (0.546) 1181 (0.580)
H2 608 (0.299) 570 (0.280)
H3 271 (0.134) 271 (0.133)
H4 11 (0.006) 5 (0.003)
H5 & H5v 30 & 1 (0.015 & 0.0005) 9 & 0 (0.004)*
*Statistical comparison versus reference group P  .01.
ZPI R67X POLYMORPHISM INCREASES DVT RISK 181BLOOD, 1 JULY 2006  VOLUME 108, NUMBER 1
For personal use only.on July 17, 2014. by guest  bloodjournal.hematologylibrary.orgFrom 
function or reduced levels of ZPI might increase the risk of
thrombosis. Thus, deficiency of its cofactor PZ seems to increase
the risk of thrombosis.7 Moreover, the PZ/ZPI system is impaired
by antiphospholipid antibodies, increasing the thrombotic risk of
patients with this autoimmune disease.21 A recent report identifies
nonsense mutations in the ZPI gene that significantly increase the
risk of venous thrombosis.8 Our results further support the rel-
evance of this serpin on hemostasis and identify a genetic risk
factor for venous thrombosis. The results of this case-control study
suggest that the ZPI H5 haplotype, featured by a stop codon at
position 67, might be an independent risk factor for venous
thrombosis. The prevalence of the ZPI Arg67Stop polymorphism is
slightly lower than that of the FV Leiden or PT 20210GA, but the
associated risk is similar. Moreover, this polymorphism is associ-
ated with familial history of thrombosis. Our data support that the
ZPI Arg67Stop polymorphism could be included in the list of
markers of thrombophilia. The study performed in New Zealand
also identified this polymorphism.8 However, further studies in
other populations are required to confirm the thrombotic role of the
ZPI Arg67Stop nonsense polymorphism. Another limitation of this
study derives from the inclusion of patients with recurrence, which
could produce a biased estimate of venous thromboembolic risk.
The optimal design to assess recurrences is a prospective study
after a first event. We have reanalyzed all the data considering only
patients with a single episode of thrombosis (n  738). This group
was matched for age, race, and sex with controls, and the results
were equivalent (multivariate analysis: FV Leiden: P  .001
[OR  5.54, 95% CI: 3.4-9.0]; PT 20210GA: P  .001
[OR  5.37, 95% CI: 3.1-9.3]; and ZPI Arg67Stop: P  .011
[OR  3.35, 95% CI: 1.3-8.6]).
All available information supports a relatively high incidence of
nonsense mutations in the ZPI gene among patients with venous
thrombosis: 4.4% in New Zealand population8 and 3.0% in Spanish
population. Accordingly, genetic modifications causing premature
stop codons in the ZPI (polymorphisms or mutations) will probably
increase the risk of venous thrombosis. The functional consequence
of these nonsense mutations seems obvious. The stop codon,
especially that located in the N-terminus region of the protein
(position 67), should cause circulating deficiency of this serpin.
Certainly, it is necessary to determine the levels of ZPI in carriers
of these nonsense modifications to confirm such suggestion, but the
expected ZPI deficiency of these patients might explain the
increased risk of venous thrombosis. However, these results are
partially conflictive with the recent report of the Leiden Thrombo-
philia Study (LETS).22 This study did not detect a relationship
between the plasmatic level of ZPI and venous thrombosis.22 This
apparent discrepancy might be explained by the relatively low
frequency of nonsense changes (probably  4% in the LETS
study), most of them in heterozygous state. Thus, the normal levels
of ZPI in noncarriers of the ZPI Arg67Stop polymorphism or the
Trp303Stop mutation might mask any possible moderate defi-
ciency of ZPI associated with this polymorphism in
heterozygous state.
Our study identifies a nonsense polymorphism. Although it
might seem that a genetic change causing a stop mutation never
would have been evolutionary selected, there are old and recent
references of this process. First, the origin of a stop codon might
provide an evolutionary advantage that explains its selection. Thus,
the common Arg577Stop nonsense polymorphism of the ACTN3
gene has a beneficial effect on the function of skeletal muscle in
generating forceful contractions at high velocity, increasing sprint
performance,23 or a stop codon polymorphism of Toll-like receptor
5 is associated with resistance to systemic lupus erythematosus.24
Other nonsense polymorphisms, such as the Tyr319Stop polymor-
phism of the SLC6A18 gene,25 have no significant relevance. In
contrast, there are examples of nonsense polymorphisms associat-
ing with different pathologies. Thus, the frequency of the 446GT
(Trp149Stop) polymorphism of the ARLTS1, a member of the ADP
ribosylation family, was similar in controls and patients with
sporadic tumors but was significantly more common among
patients with familial cancer.26 Finally, the common nonsense
polymorphism affecting the complement C9 gene (Arg95Stop),
which is present in 6.7% of the Japanese population,27 causes
complement deficiency when present in homozygous state. Other
polymorphisms affecting serpin-encoding genes might cause defi-
ciency of the affected protein. The best example is the deficiency of
1-antitrypsin associated with the Z variant (Glu342Lys), which
associates with emphysema and liver cirrhosis in homozygous
Table 5. Clinical features of patients according to the ZPI haplotypes
No.
Age first episode, y,
median (range)
Recurrence,
no. (%)
Other risk
factors, no. (%)
Familial
history, no. (%)
H1/H1 (reference group) 297 46 (36–60) 77 (25.9) 54 (18.2) 40 (13.5)
H1/H2 337 45 (32–58) 95 (28.2) 77 (22.8) 69 (20.5)
H1/H3 163 45 (32–56) 46 (28.2) 42 (25.8) 21 (12.9)
H1/H4 3 21 (18–65) 0 0 0
H1/H5 & H1/H5v 17 & 1 47 (32–62) 3 (16.7) 7 (38.9)* 7 (38.9)*
H2/H2 90 43 (33–59) 28 (31.1) 21 (23.3) 20 (22.2)*
H2/H3 77 45 (34–53) 19 (24.7) 13 (16.9) 12 (15.6)
H2/H4 5 53 (36–67) 0 0 1 (20.0)
H2/H5 9 50 (38–65) 5 (55.6) 1 (11.1) 2 (22.2)
H3/H3 13 41 (28–61) 4 (30.8) 2 (15.4) 1 (7.7)
H3/H4 3 29 (25–62) 0 1 (33.3) 2 (66.7)
H3/H5 2 57 (50–65) 2 (100) 0 1 (50.0)
H5/H5 1 62 1 (100) 0 1 (100)
Haplotype carrier
H2 608 45 (33–58) 147 (28.4) 111 (21.4) 104 (20.1)*
H3 271 45 (32–56) 71 (27.5) 58 (22.5) 37 (14.3)
H4 11 44 (25–64) 0 1 (9.1) 3 (27.3)
H5 & H5v 31 46 (32–62) 11 (36.7) 9 (30.0) 11 (36.7)†
*P  .05.
†P  .001.
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state.28 To the best of our knowledge, the ZPI Arg67Stop is the first
nonsense polymorphism identified in serpins that increases the risk
of venous thrombosis in heterozygous state.
Finally, we identified the first case homozygous for a nonsense
mutation in the ZPI gene. Certainly, this patient suffered from
recurrent venous thrombosis, but the first episode was quite late (at
62 years old) and there were additional risk factors present
(hormone replacement therapy). Moreover, the carrier has no
additional pathologies. The features of this ZPI knock-out patient
are similar to that described for another anticoagulant serpin that
shares additional structural similarities with the ZPI, the heparin
cofactor II. Our group also identified the first case with heparin
cofactor II homozygous deficiency that has no significant patho-
logic consequences.29 In contrast, complete antithrombin defi-
ciency is associated with embryonic lethality in mice and hu-
mans.30 All of these data support that many serpins are not
necessary for embryo development, but they are necessary to the
control of serine proteases in the adult life. Moreover, an important
redundancy between different serpins and other inhibitory mecha-
nisms should exist to explain the absence of significant pathologies
under complete deficiency of some serpins such as ZPI or heparin
cofactor II.
In conclusion, our results support that the ZPI Arg67Stop
nonsense polymorphism might be considered as a mild genetic risk
factor for venous thrombosis. This polymorphism has lower
prevalence but similar risk than the FV Leiden or prothrombin
20210A variants (ORs 3.32, 5.32, and 4.23, respectively). All
available data support that the ZPI is a good candidate to play a
significant role in thrombosis. Other genetic changes affecting this
serpin, including other polymorphisms or unusual mutations, might
be present in some of the so far idiopathic thrombosis, and
consequently, functional and genetic analysis of the ZPI would be
performed in thrombophilic studies.
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